The Global Health Innovative Technology (GHIT) Fund has announced a total of 2.86 billion yen to support 10 partnerships to develop new lifesaving drugs, vaccines, and diagnostics for malaria, tuberculosis, dengue, leishmaniasis, and schistosomiasis. This includes three new projects and seven that will receive continued funding.

Projects & Investments-

Treating schistosomiasis in preschool-aged children: development, registration and access to L-praziquantel orally disintegrating tablet formulation- ¥452,329,597

 Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes- ¥489,273,750

Preclinical development of a novel mechanism-of-action antimalarial drug with multistage activity- ¥536,822,427

Preclinical development of a new class of Plasmodium DHODH inhibitor for the treatment of malaria- ¥421,418,717

Live attenuated prophylactic vaccine for leishmaniasis- ¥399,898,983

Mitsubishi Tanabe Lead Optimization of Anti-Malarials- ¥192,247,534

New Hit-to-Lead Activity for New Anti-Malarials between MMV and Takeda- ¥52,800,000

Hit-to-Lead Development of Novel anti-TB Natural Products- ¥119,244,000

Further development of a new asexual blood-stage malaria vaccine candidate- ¥93,057,133

Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis and Malaria- ¥100,000,000